Singapore markets closed

Biodexa Pharmaceuticals Plc (BDRX)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
1.1900-0.0500 (-4.03%)
At close: 04:00PM EDT
1.2400 +0.05 (+4.20%)
After hours: 07:26PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.2400
Open1.3700
Bid1.1700 x 100
Ask1.2100 x 600
Day's range1.1600 - 1.3700
52-week range0.6700 - 17.6000
Volume480,801
Avg. volume2,950,441
Market cap5.218M
Beta (5Y monthly)1.53
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    Posting of Annual Report & Notice of AGM - Total Voting Rights

    May 15, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Posting of Annual Report & Notice of AGM Total Voting Rights Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announces that its Notice of Annual General Meeting (“AGM”) was posted to shareholders yesterday, along with the Annual Report for the year ended 31 December 2023. The document is a

  • GlobeNewswire

    Biodexa’s Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual Meeting

    April 30, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa’s Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual Meeting Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is pleased to announce that’s it

  • GlobeNewswire

    Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)

    April 26, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for theTreatment of Familial Adenomatous Polyposis (FAP) Worldwide rights come with $17 million in non-dilutive grant funding for Pivotal Phase 3 trial in FAP An estimated 100,000 in U.S. and Europe are afflicted with FAP, precancerous polyps that typically lead to surgical removal of the colon and/or rectum In FAP, eRapa holds the potential of delaying or